Cancer incidence for patients with type 2 diabetes exposed to oral hypoglycemics: are there differences between agents?

Project number: 
06-017
Approval date: 
Monday, April 21, 2008
Principal Investigator: 
Johnson,Jeff
Institution: 
University of British Columbia (UBC)
Funding Agency: 
Alberta Health Services (U of Alberta),Unknown,Canadian Institutes of Health Research(CIHR),Michael
Datasets requested: 
Deaths (BC Vital Statistics Agency)
Medical Services Plan (BC Ministry of Health)
Consolidation - demographic (Ministry of Health)
PharmaNet
Hospital Separations (BC Ministry of Health)
Consolidation registry (Ministry of Health)
bc cancer
consolidation - census geocodes
Research objective: 

The elevated risk of cancer among individuals with type 2 diabetes is being increasingly recognized. Further to these findings the objective of our research is to further assess this association between type 2 diabetes and cancer. Specific hypotheses to be tested are:

1) Relative to people without diabetes, people with type 2 diabetes will have an increased risk of cancer (overall and specific sites), even prior to diabetes index.

2) Relative to people without diabetes, people with type 2 diabetes on sulfonylurea and/or insulin therapy, will have an increased risk of developing cancer (overall and various sites) compared to people with type 2 diabetes on metformin therapy.

3) What is the association between diabetes/hypoglycemics and cancer risk in Chinese, South Asian and Non-Asian ethnicities?

Publications: 

Journal Publication

  • Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, Keskimäki I, Badrick E, Renehan AG, Buchan IE, Bowker SL, Minhas-Sandhu JK, Zafari Z, Marra C, Johnson JA, Stricker BH, Uitterlinden AG, Hofman A, Ruiter R, de Keyser CE, MacDonald TM, Wild SH, McKeigue PM, Colhoun HM; Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015;58:493-504.
  • Colmers IN, Majumdar SR, Yasui Y, Bowker SL, Marra CA, Johnson JA. "Detection bias and overestimated of bladder cancer risk in type 2 diabetes: a matched cohort study." Diabetes Care 2013 Oct;36(10):3070-5. doi: 10.2337/dc13-0045. Epub 2013 Aug 29.
  • Colmers IN, Majumdar SR, Yasui Y, Bowker SL, Marra CA, Johnson JA. Detection Bias and Overestimation of Bladder Cancer Risk in Type 2 Diabetes: A Matched Cohort Study.  Diabetes Care 2013;36:3070-5.
  • Johnson JA, Bowker SL, Richardson K, Marra C. Time-varying incidence of cancer after the onset of type 2 diabetes: Evidence of potential detection bias. Diabetologia 2011;54:2263-71.
  • Bowker SL, Richardson K, Marra C, Johnson JA. Risk of breast cancer after onset of type 2 diabetes: Evidence of detection bias in post-menopausal women.  Diabetes Care 2011;34:2542-4.

Page last revised: December 5, 2017